While diet drug Acomlia / Zimulti (rimonabant) seems unlikely to make it to the U.S. market for at least a couple of years, Sanofi-Aventis appears hopeful the pill — which already is on sale in Europe — may soon be approved there for treatment of type 2 diabetes.Executive Vice President Hanspeter Spek, talking to financial analysts on Aug. 1st, said the European Medicines Agency (EMEA) “is reviewing the data” from the SERENADE study in which diabetics not treated with other diabetic medications experienced significant improvements in blood sugar control vanuatu acomplia.In the study, blood sugar levels of half of the patients on Acomplia fell to below 7 percent — the target set by the American Diabetes Association for good glucose control — and the patients taking Acomplia lost almost 15 pounds of weight compared to 6 pounds for those on a placebo.The trial showed that HbA1c levels (a measure of blood glucose) in patients with a baseline average of 7.9 , where can acomplia be bought from a reputable pharmacy? , who took a 20 mg Acomplia pill once daily fell 0.8 percentage points compared to a drop of 0.3 points in those taking a placebo.Patients with an HbA1c level of at least 8.5 when they started taking acomplia or rimonabant or zimulti saw their their blood sugar level decrease 1.9 points compared to 0.7 points in patients on a placebo *vanuatu acomplia

---

Overweight Americans eager to try diet drug rimonabant will not be able to buy it at their neighborhood pharmacy in the next couple of years.vanuatu acomplia

The diet drug, which has now been taken by more than 200,000 obese and overweight patients in Europe and a handful of other countries, will not be resubmitted to the FDA for approval in the United States anytime soon, Sanofi-Aventis officials made clear on August 1.

Executive Vice President Hanspeter Spek, talking to financial analysts, tried to emphasize acomplia without prescription that Sanofi’s decision in June to withdraw its FDA application to sell Zimulti (called acomplia or rimonabant or zimulti elsewhere in the world,acomplia without prescription) did not mean that the diet drug would never be seen in the U.S. market.

“The FDA has formally acknowledged that we have a strong file and has given us notice that they are absolutely ready to see us again with this file as soon as it can be completed by additional data confirming the benefit-risk profile of Zimulti in the United States,” Spek said.

During his presentation and in response to questions, Spek repeatedly said a resumption of efforts to get the FDA to approve Zimulti — which was originally submitted to the agency in 2005 — would be “data driven.”acomplia without prescription

A major concern of an FDA advisory panel, which in June unanimously recommended against permitting sale of Zimulti in the United States, was that Sanofi had presented insufficient data regarding such side-effects as depression and suicidality to warrant approval of the drug for long-term use.

“Data driven first of all means of course whatever may come out of the regular reporting of side effects (on use of acomplia or rimonabant or zimulti by patients in Europe and elsewhere) of course we will share with the FDA,” Spek said.

---

Merck’s development of taranabant,acomplia diet pills, a diet drug which has been described as a competitor for Acomplia (acomplia diet pills), must be going pretty well because the pharmaceutical giant has brought back top marketeer Len Tacconi to serve as the drug’s global brand leader.

While taranabant, a cannabinoid-1 (CB-1) receptor inverse agonist that has a mechanism of action similar to that of Sanofi-Aventis’ rimonabant, is still in Phase III trials, it now appears that the Merck drug may well beat Acomplia to the U.S. market.

Merck continues to say little about taranabant, but Sanofi-Aventis withdrew its application to market acomplia diet pills in the U.S. in June after an FDA advisory panel recommended against approving it due to concerns over psychiatric side effects.

Merck has said it intends to file for FDA approval of taranabant in 2008, and Sanofi — which continues to market rimonabant in Europe and some other countries — now is not expected to refile for the U.S.before the Merck filing.

Tacconi, who left Merck less than a year ago to become president of Discovery Health, spent a decade with Merck orchestrating high-spending consumer marketing campaigns for drugs that included Singulair, Zocor and Vioxx.

Before joining Merck, Tacconi had led North American marketing for Weight Watchers.